Literature DB >> 2457773

Palliative transposition of venous return. Long-term follow-up.

R A Humes1, D J Driscoll, D D Mair, G K Danielson, D C McGoon.   

Abstract

A palliative operation to create intraatrial transposition of venous return without concomitant closure of an associated ventricular septal defect (palliative Mustard or Senning operation) has been used primarily for patients with a combination of transposition of the great arteries, ventricular septal defect, and pulmonary vascular obstructive disease. We evaluated the results in all 15 patients (median age 13 years) who had this procedure at the Mayo Clinic between 1973 and 1979. There were two (13%) operative deaths. One patient was lost to long-term follow-up. Of the 12 operative survivors for whom follow-up data were available, 11 reported subjective improvement in exercise tolerance and activity level. There were seven late deaths: six from cardiovascular problems and one from an accident. There are five survivors currently alive (average 10.8 years after operation). Patients who survived the operation for more than 5 years had a significantly (p less than 0.05) lower pulmonary resistance preoperatively than those who survived less than 5 years. The hemoglobin level decreased from 21.1 gm/dl before operation to 18.4 gm/dl, and arterial saturation was increased from 64% to 85% at an average of 9 years after operation. We conclude that this operation produces subjective improvement and lessens hypoxemia and polycythemia. In some patients, palliation may be achieved for 10 years or longer.

Entities:  

Mesh:

Year:  1988        PMID: 2457773

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  2 in total

1.  Palliative Mustard operation for transposition of the great arteries: late results after 15-20 years.

Authors:  G Sagin-Saylam; J Somerville
Journal:  Heart       Date:  1996-01       Impact factor: 5.994

2.  Palliative Senning in the Treatment of Congenital Heart Disease with Severe Pulmonary Hypertension.

Authors:  Juliano Gomes da Penha; Leina Zorzanelli; Antonio Augusto Barbosa-Lopes; Edimar Atik; Leonardo Augusto Miana; Carla Tanamati; Luiz Fernando Caneo; Nana Miura; Vera Demarchi Aiello; Marcelo Biscegli Jatene
Journal:  Arq Bras Cardiol       Date:  2015-08-18       Impact factor: 2.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.